Myocardial contractile responsiveness to endothelin-1 in the post-infarction rat model of heart failure: effects of chronic quinapril

J Mol Cell Cardiol. 2001 Nov;33(11):2023-35. doi: 10.1006/jmcc.2001.1467.

Abstract

Cardiac endothelin-1 (ET-1) levels and ET receptor expression are increased in congestive heart failure (CHF). In order to determine whether this results in increased responsiveness of ET-A or ET-B receptors to ET-1, we evaluated the contractile effects of ET-1 in isolated papillary muscles isolated from hearts of control rats and from rats 4 weeks post myocardial infarction (MI) having received no therapy or chronic quinapril therapy. The ET-1 dose-response was biphasic in normal muscles. The use of the selective ET-A receptor antagonist BQ123 and the selective ET-B receptor antagonist BQ788 revealed that the initial decrease in tension was the result of ET-B receptor stimulation. Blockade of nitric oxide (NO) production with L-NAME abolished the initial decrease in tension. MI resulted in CHF that was partially reversed by quinapril. In MI, the positive inotropic effects of ET-1 were enhanced due to the loss of the initial ET-B receptor mediated decrease in tension, as well as an increase in the positive inotropic effects of ET-A receptors. This was associated with an increase in ET-A and ET-B receptor mRNA and a decrease in cardiac ecNOS protein. Four weeks of therapy with quinapril attenuated the positive inotropic effects of ET-1 and prevented the increase in ET-A receptor mRNA. Although quinapril did not restore the effects of ET-B receptor stimulation or prevent the increase in ET-B mRNA, it did restore cardiac ecNOS protein expression. Thus, the inotropic response to ET-1 is biphasic due to an overall positive inotropic effect of ET-A receptor stimulation and an ET-B receptor mediated decrease in contractility at low ET-1 concentrations which appears to be mediated by cardiac ecNOS (NO). In post-MI CHF, responsiveness to ET-A receptors increases and the ET-B mediated negative inotropic response is lost despite an increase in both receptor subtypes. Quinapril therapy attenuates these effects and normalises cardiac ecNOS protein.

MeSH terms

  • Angiotensin-Converting Enzyme Inhibitors / pharmacology
  • Animals
  • Antihypertensive Agents / pharmacology
  • Binding, Competitive
  • Body Weight
  • Dose-Response Relationship, Drug
  • Endothelin-1 / metabolism*
  • Endothelium, Vascular / cytology
  • Endothelium, Vascular / metabolism
  • Heart Failure / metabolism
  • Hemodynamics
  • Isoquinolines / pharmacology*
  • Kinetics
  • Male
  • Muscles / metabolism
  • Myocardial Contraction*
  • Myocardial Infarction / metabolism*
  • Myocardium / cytology
  • Myocardium / metabolism
  • Nitric Oxide Synthase / metabolism
  • Nitric Oxide Synthase Type III
  • Oligopeptides / pharmacology
  • Organ Culture Techniques
  • Organ Size
  • Papillary Muscles / metabolism
  • Peptides, Cyclic / pharmacology
  • Piperidines / pharmacology
  • Protein Binding
  • Quinapril
  • RNA, Messenger / metabolism
  • Rats
  • Rats, Wistar
  • Receptor, Endothelin A
  • Receptor, Endothelin B
  • Receptors, Endothelin / metabolism
  • Reverse Transcriptase Polymerase Chain Reaction
  • Tetrahydroisoquinolines*
  • Time Factors
  • Vasoconstrictor Agents / pharmacology
  • Viper Venoms / pharmacology

Substances

  • Angiotensin-Converting Enzyme Inhibitors
  • Antihypertensive Agents
  • Endothelin-1
  • Isoquinolines
  • Oligopeptides
  • Peptides, Cyclic
  • Piperidines
  • RNA, Messenger
  • Receptor, Endothelin A
  • Receptor, Endothelin B
  • Receptors, Endothelin
  • Tetrahydroisoquinolines
  • Vasoconstrictor Agents
  • Viper Venoms
  • sarafotoxins s6
  • BQ 788
  • Nitric Oxide Synthase
  • Nitric Oxide Synthase Type III
  • Nos3 protein, rat
  • Quinapril
  • cyclo(Trp-Asp-Pro-Val-Leu)